AbbVie reported earnings of $ 3.82 per ABBV share on Oct 30, 2026, beating analysts' expectations by
| Report Date | Oct 30, 2026 |
|---|---|
| Forecasted EPS | $ 3.73 |
| Earnings Per Share (Surprise) | $ 3.82 (+$ 0.09) |
| Last Year's EPS | $ 2.50 |
| EPS YoY Change |
Out of the last 63 earnings reporting periods, AbbVie beat analysts’ expectations 51 times and fell short of expectations 2 time(s). AbbVie reported earnings per share of $ 3.82 in the last report surpassing an estimated EPS of $ 3.73 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Oct 30, 2026 | $ 3.73 | $ 3.82 | $ 1.86 | |
| Jul 31, 2026 | $ 3.61 | $ 3.65 | $ 2.97 | |
| Apr 29, 2026 | $ 2.59 | $ 2.65 | $ 2.46 | |
| Feb 4, 2026 | $ 2.65 | $ 2.71 | $ 2.16 | |
| Oct 31, 2025 | $ 1.77 | $ 1.86 | $ 3.00 | |
| Jul 31, 2025 | $ 2.88 | $ 2.97 | $ 2.65 | |
| Apr 25, 2025 | $ 2.38 | $ 2.46 | $ 2.31 | |
| Jan 31, 2025 | $ 2.98 | $ 2.16 | $ 2.79 | |
| Oct 30, 2024 | $ 2.92 | $ 3.00 | $ 2.95 | |
| Jul 25, 2024 | $ 2.57 | $ 2.65 | $ 2.91 | |
| Apr 26, 2024 | $ 2.26 | $ 2.31 | $ 2.46 | |
| Feb 2, 2024 | $ 2.76 | $ 2.79 | $ 3.60 | |
| Oct 27, 2023 | $ 2.86 | $ 2.95 | $ 3.66 | |
| Jul 27, 2023 | $ 2.79 | $ 2.91 | $ 3.37 | |
| Apr 27, 2023 | $ 2.44 | $ 2.46 | $ 3.24 | |
| Feb 9, 2023 | $ 3.54 | $ 3.60 | $ 3.31 | |
| Oct 28, 2022 | $ 3.56 | $ 3.66 | $ 3.33 | |
| Jul 29, 2022 | $ 3.31 | $ 3.37 | $ 3.11 | |
| Apr 29, 2022 | $ 3.14 | $ 3.24 | $ 2.95 | |
| Feb 2, 2022 | $ 3.29 | $ 3.31 | $ 2.92 |
AbbVie’s stock was trading at $ 290.97 on Oct 29, 2026 a day before the last earnings report was released.Following the release of the earnings report, ABBV’s price decreased to $ 288.94 on Oct 31, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Oct 30, 2026 | $ 3.82 | $ 290.97 | $ 288.94 | |
| Jul 31, 2026 | $ 3.65 | $ 257.61 | $ 245.08 | |
| Apr 29, 2026 | $ 2.65 | $ 197.69 | $ 211.32 | |
| Feb 4, 2026 | $ 2.71 | $ 225.66 | $ 219.02 | |
| Oct 31, 2025 | $ 1.86 | $ 228.20 | $ 211.96 | |
| Jul 31, 2025 | $ 2.97 | $ 189.31 | $ 195.22 | |
| Apr 25, 2025 | $ 2.46 | $ 180.37 | $ 192.34 | |
| Jan 31, 2025 | $ 2.16 | $ 175.65 | $ 190.14 | |
| Oct 30, 2024 | $ 3.00 | $ 189.45 | $ 203.87 | |
| Jul 25, 2024 | $ 2.65 | $ 176.21 | $ 185.16 | |
| Apr 26, 2024 | $ 2.31 | $ 167.29 | $ 161.52 | |
| Feb 2, 2024 | $ 2.79 | $ 167.59 | $ 171.26 | |
| Oct 27, 2023 | $ 2.95 | $ 145.20 | $ 141.89 | |
| Jul 27, 2023 | $ 2.91 | $ 141.90 | $ 150.85 | |
| Apr 27, 2023 | $ 2.46 | $ 161.80 | $ 151.12 | |
| Feb 9, 2023 | $ 3.60 | $ 144.61 | $ 152.05 | |
| Oct 28, 2022 | $ 3.66 | $ 153.50 | $ 146.40 | |
| Jul 29, 2022 | $ 3.37 | $ 149.75 | $ 140.22 | |
| Apr 29, 2022 | $ 3.24 | $ 156.31 | $ 147.87 | |
| Feb 2, 2022 | $ 3.31 | $ 137.00 | $ 140.73 |
AbbVie released its most recent earnings reports in October 2026, July 2026, April 2026, February 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
AbbVie beat analysts’ expectations during the last earnings period by
